2022 Research Highlights

Characterized Cav3.3 potentiators using a high-throughput in vitro FLIPR assay.

Identified biomarker features for cancer contexts in which RTCP1 is required.

Characterized the RNA editing activity of deaminases using an in vitro assay.

Investigated nanobody binding affinities to improve cancer immunotherapy.

Analyzed IDH1-mutant skin cutaneous melanoma subtypes.

Developing a tool to link single-neuron transcriptomes to synaptic connectivity.

Characterized the development of EZR and RhoA gene dependencies in colorectal cancer organoids.

Investigated the functional association between a drug candidate and CARHSP1 in cancer cell lines.

labelled cancer cells with biotin to facilitate targeted anticancer therapies.

Used Single-cell ATAC-sequencing to build a pipeline and analyze the phenomenon of epigenetic erosion within neurons.

Used machine learning to examine structural variants.

Characterized ITGB1 and SLC39A9 mutations in cancer cell lines as well as developed novel organoid for use in further characterization.

Prime edited blood cancer mutations in spliceosome protein SF3B1.

Used single-cell RNA sequencing analysis to investigate gene expression associations of autoimmune disease.

Evolved a small reverse transcriptase for improved activity in the prime editing system.

Examined impact of post-translational modifications on Down syndrome.

Developed a computational tool to detect Survival Motor Neuron mutations in Whole Exome Sequencing data.

Created a pipeline to serve drug side-effect information to the Biomedical Data Translator Project.

Investigated a new immortalization method for pediatric low-grade glioma cell lines.